Yoda Pharmaceuticals Inc. (7829.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Yoda Pharmaceuticals Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Operating income | -221.91 m TWD | -391.87 m TWD |
| EBIT | -192.19 m TWD | -407.20 m TWD |
| Net income | -192.19 m TWD | -407.22 m TWD |
| Diluted EPS – continuing operations | -2.31 TWD | -4.89 TWD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Yoda Pharmaceuticals Inc.
Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson"s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. was incorporated in 2019 and is based in Grand Cayman, the Cayman Islands.
More stocks
- Solocal Group SA (LOCAL.PA)
- Sunty Development Co Ltd (3266.TW)
- Heran Co Ltd (5283.TW)
- Srivichaivejvivat Public Company Limited (VIH.BK)
- Daol Investment & Securities (030210.KS)
- Tway Air Co Ltd (091810.KS)
- JD Bancshares Inc (JDVB)
- Carlo Gavazzi Holding AG (GAV.SW)
- Protara Therapeutics, Inc. (TARA)
- Cystech Electronics Corp (6651.TWO)
- Aiptek International Inc (6225.TW)
- ESTec Corporation (069510.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.